How to maintain healthy bowel habits:
Strain |
Lactobacillus acidophilus, LA-5® & Bifidobacterium, BB-12® 3 |
Potency | 4 billion CFU/day of each strain 3 |
Duration | Commence LA-5® & BB-12® the same day as starting the antibiotics, continue for a week longer than the antibiotics, consume the probiotic product a few hours after intake of antibiotics.3 |
The probiotic strain Bifidobacterium, BB-12® is the world’s most documented probiotic bifidobacterium. It has been extensively studied and has been associated with improved outcomes across various health areas.
BB-12® is a trademark of Chr. Hansen A/S
The probiotic strain Lactobacillus acidophilus, LA-5® has demonstrated benefits, for example, in gastrointestinal health when used in combination with Bifidobacterium, BB-12®.
LA-5® and BB-12® are trademarks of Chr. Hansen A/S
1. Francino MP. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. Front Microbiol. 2016;6:1543-. (PubMed)
2. Walker WA. The importance of appropriate initial bacterial colonization of the intestine in newborn, child, and adult health. Pediatr Res. 2017;82(3):387-95. (PubMed)
3. Chatterjee S, et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India. 2013;61(10):708-12. (PubMed)
4. de Vrese M, et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J Dairy Res. 2011;78(4):396-403. (PubMed)
5. Szajewska H, et al. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr. 2006;149(3):367-72. (PubMed)
6. Allen SJ, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382(9900):1249-57. (PubMed)
7. Giannelli FR. Antibiotic-associated diarrhea. Journal of the American Academy of PAs. 2017;30(10):46-7. (PubMed)
8. Coté GA, Buchman AL. Antibiotic-associated diarrhoea. Expert Opin Drug Saf. 2006;5(3):361-72. (PubMed)
9. Agamennone V, et al. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands. BMC Gastroenterol. 2018;18(1):103. (PubMed)
10. McFarland LV, Goh S. Preventing pediatric antibiotic-associated diarrhea and Clostridium difficile infections with probiotics: a meta-analysis. World Journal of Meta-Analysis. 2013;1(3):102-20. (Source)
11. Alam S, Mushtaq M. Antibiotic associated diarrhea in children. Indian Pediatr. 2009;46(6):491-6. (PubMed)
12. Koo H, et al. Individualized recovery of gut microbial strains post antibiotics. npj Biofilms and Microbiomes. 2019;5(1):30. (PubMed)
13. Palleja A, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255-65. (PubMed)
14. De La Cochetiere MF, et al. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol. 2005;43(11):5588-92. (PubMed)
15. Dethlefsen L, et al. The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing. PLoS Biol. 2008;6(11):e280. (PubMed)
16. Jakobsson HE, et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836. (PubMed)
17. Jernberg C, et al. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010;156(Pt 11):3216-23. (PubMed)
18. Nasiri MJ, et al. Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: A systematic review and meta-analysis. Anaerobe. 2018;50:32-7. (PubMed)
19. Sugden R, et al. Combatting antimicrobial resistance globally. Nature Microbiology. 2016;1(10):16187. (PubMed)
20. Martins FS, et al. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol. 2009;191(8):623-30. (PubMed)
21. Fooks LJ, Gibson GR. Mixed culture fermentation studies on the effects of synbiotics on the human intestinal pathogens Campylobacter jejuni and Escherichia coli. Anaerobe. 2003;9(5):231-42. (PubMed)
22. Tabasco R, et al. Lactobacillus acidophilus La-5 increases lactacin B production when it senses live target bacteria. Int J Food Microbiol. 2009;132(2-3):109-16. (PubMed)
23. Lopez P, et al. Distinct Bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol. 2010;138(1-2):157-65. (PubMed)
24. Sheikhi A, et al. Probiotic Yogurt Culture Bifidobacterium Animalis Subsp. Lactis BB-12 and Lactobacillus Acidophilus LA-5 Modulate the Cytokine Secretion by Peripheral Blood Mononuclear Cells from Patients with Ulcerative Colitis. Drug Res (Stuttg). 2016;66(6):300-5. (PubMed)
Learn more about what probiotics are and how they can benefit your health
Learn how to review the evidence when considering probiotic strains and effects
Read more about some of the world’s most documented probiotic strains and their diverse, beneficial health effects